Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
31 /100
MEDIUM RISK
Score updated Oct 13, 2026

MLYS — Mineralys Therapeutics, Inc. Dilution Risk Tracker

Track MLYS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track MLYS — Get alerts when the score changes →

As of October 13, 2026, Mineralys Therapeutics, Inc. (MLYS) has a DilutionWatch DilutionScore of 31/100, rated MEDIUM dilution risk. Mineralys Therapeutics, Inc. has a market capitalization of $1.97B, 88.41M shares outstanding, 217 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
32
💰 Cash Runway
40
📊 Float Risk
25
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for MLYS.
🔔 Track MLYS — Get forecast alerts →

Market Data

Market Cap$1.97B
Shares Outstanding88.41M
Float60.37M
Cash$138.27M
Debt$100.0K
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore31/100DilutionWatch score record
Shares Outstanding88.41MVerified float table or market cache
Public Float60.37MVerified float table or market cache
Market Cap$1.97BMarket data cache
Cash Runway14.2 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 5, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 4.0% shares (2026Q1 vs prior)
217 institutional holders · 105.75M shares
#1 Catalys Pacific, LLC 7.90M shares
#2 RA CAPITAL MANAGEMENT, L.P. 7.69M shares
#3 SAMSARA BIOCAPITAL, LLC 5.87M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest7.81M
Days to Cover5.2
% of Float12.9%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-12
xbrl XBRL CONVERTIBLE 2025-02-12
4 INSIDER TRANSACTION 2026-04-02
4 INSIDER TRANSACTION 2026-04-02
4 INSIDER TRANSACTION 2026-03-31
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual MLYS Dilution Snapshot

Mineralys Therapeutics, Inc. (MLYS) has a DilutionScore of 31/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

MLYS's DilutionScore is currently 31/100 (Medium risk), with 2 score changes tracked over 89 days. The score deteriorated from 41/100 (Medium risk).

Period Score Risk Level Duration
Aug 29 – Oct 13, 202631/100MEDIUM46 days
Aug 22 – Aug 28, 202641/100MEDIUM7 days
Jul 16 – Aug 21, 202649/100MEDIUM36 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

MLYS shares outstanding have increased 4.2% from 79.14M (Mar 2026) to 82.50M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 18, 202682.50M60.37M▲ 0.01%
May 12, 202682.50M60.36M▲ 0.02%
May 11, 202682.50M60.35M▲ 0.12%
Apr 26, 202682.45M60.27M▲ 0.03%
Apr 18, 202682.45M60.26M▲ 0.01%
Apr 17, 202682.45M60.25M▲ 0.02%
Apr 11, 202682.45M60.24M▼ 0.49%
Apr 07, 202682.40M60.53M▼ 0.01%
Mar 20, 202682.40M60.54M▼ 0.05%
Mar 17, 202679.14M60.57M▲ 1.51%
Mar 16, 202679.14M59.67M▲ 4.12%
Mar 08, 202679.14M57.31M▼ 0.07%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track MLYS Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment MLYS files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking MLYS — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for MLYS
MLYS FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.